- MediciNova (NASDAQ:MNOV) announces positive results from a Phase 2 clinical trial evaluating MN-166 (ibudilast) for the treatment of alcohol use disorder (AUD). The results were presented virtually at the American Psychological Association Annual Meeting.
- Ibudilast significantly reduced the number of heavy drinking days compared to placebo (p=0.03).
- There was a significant effect of ibudilast on alcoholic beverage images (ALC) versus non-alcoholic beverage images (BEV) percent signal change in the bilateral ventral striatum (VS) evaluated by fMRI (p=0.02).
- Predicting Drinking by Medication: Significant interaction between ibudilast and activation in the VS on subsequent drinking (p=0.02). Patients treated with ibudilast and had attenuated VS activation drank the least in the week after the scan.
- Ibudilast significantly reduced binge drinking after 14 days of treatment.
- Shares up 10% premarket on average volume.